Showing results (221-230 of 243) with videos related to

Sort By:
Pageof 25
Oncogene|August 9, 2011
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signalingG Sala, S Traini, M D'Egidio, et al.
Clinical and Experimental Immunology|September 16, 1998
Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein familyB Silvestri, F Calderazzo, V Coppola, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 1, 1993
Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancerG. Scambia, P. Benedetti Panici, G. Ferrandina, et al.
Cancer Chemotherapy and Pharmacology|May 13, 1999
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patientsF Boccardo, A Rubagotti, D Amoroso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 1997
Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II studyF Boccardo, D Amoroso, S Iacobelli, et al.
ISRN Gastroenterology|December 6, 2012
Clinical diagnostic clues in Crohn's disease: a 41-year experienceC Quintana, L Galleguillos, E Benavides, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
Novel P53 mutations detected by FAMA in colorectal cancersF De Galitiis, K Cannita, A Tessitore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2007
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancerC Natoli, E Cianchetti, N Tinari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2012
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysisS Giacchetti, P A Dugué, P F Innominato, et al.
Oncology Reports|April 6, 2006
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding studyC Ficorella, E Ricevuto, M F Morelli, et al.
Pageof 25